medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (5)


Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease

Wenfeng Z, Yakun W, Di M, Jianping G, Chuanxin W, Chun H

Idioma: Ingles.
Referencias bibliográficas: 75
Paginas: 489-495
Archivo PDF: 579.25 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210.

  2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.

  3. Day CP, James OF. Steatohepatitis: a tale of two “hits”. Gastroenterology 1998; 114: 842-5.

  4. Li J, Lai X, Chen Y, Niu B, Gong J. Endotoxin tolerance attenuates liver ischemia/reperfusion injury by down-regulation of interleukin-1 receptor-associated kinase 4 in kupffer cells. Transplant Proc 2011; 43: 2531-5.

  5. Wang JT, Liu YL. Non-alcoholic fatty liver disease: the problems we are facing. Hepatobiliary Pancreat Dis Int 2003; 2: 334-7.

  6. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 5: 212-23.

  7. Ono M, Saibara T. Is impaired Kupffer cell function really important to the pathogenesis of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2012; 27: 622-4.

  8. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, Pecker F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014; 59: 130-42.

  9. Smith K. Liver disease: Kupffer cells regulate the progression of ALD and NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 503.

  10. Tsujimoto T, Kawaratani H, Kitazawa T, Uemura M, Fukui H. Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. Dig Dis Sci 2012; 57: 1144-51.

  11. Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liverdisease: an input for novel therapies. Dig Liver Dis 2013; 45: 543-51.

  12. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflammation 2010; 7: 1.

  13. Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013; 12: 357-63.

  14. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver 2012; 6: 149-71.

  15. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012; 16: 44-54.

  16. Luan X, Liu Y, Li M. The role of CD14 and Toll-like receptor 4 of Kupffer cells in hepatic ischemia-reperfusion injury in rats. Transplant Proc 2012; 44: 937-41.

  17. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, et al. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-16.

  18. Bazil V, Strominger JL. Shedding as a mechanism of downmodulation of CD14 on stimulated human monocytes. J Immunology 1991; 147: 1567-74.

  19. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-3.

  20. Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, Shinohara Y, Kato S, et al. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PLoS One 2013; 8: e65211.

  21. Tonan T, Fujimoto K, Qayyum A, Morita Y, Nakashima O, Ono N, Kage M, et al. CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: superparamagnetic iron oxide-magnetic resonance image and pathologic correlation. J Gastroenterol Hepatol 2012; 27: 789-96.

  22. Fukada H, Yamashina S, Izumi K, Komatsu M, Tanaka K, Ikejima K, Watanabe S. Suppression of autophagy sensitizes Kupffer cells to endotoxin. Hepatol Res 2012; 42: 1112-8.

  23. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis. J Hepatol 2007; 47: 571-9.

  24. Ye D, Li FY, Lam KS, Li H, Jia W, Wang Y, Man K, et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 1058-67.

  25. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-104.

  26. Sun K, Chen Y, Liang SY, Liu ZJ, Liao WY, Ou ZB, Tu B, et al. Effect of taurine on IRAK4 and NF-kappa B in Kupffer cells from rat liver grafts after ischemia-reperfusion injury. Am J Surg 2012; 204: 389-95.

  27. Liu ZJ, Yan LN, Li XH, Xu FL, Chen XF, You HB, Gong JP. Up-regulation of IRAK-M is essential for endotoxin tolerance induced by a low dose of lipopolysaccharide in Kupffer cells. J Surg Res 2008; 150: 34-9.

  28. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int 2007; 6: 572-8.

  29. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013; 14: 996-1006.

  30. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 2012; 287: 40161-72.

  31. Ajamieh H, Farrell G, Wong HJ, Yu J, Chu E, Chen J, Teoh N. Atorvastatin protects obese mice against hepatic ischemia- reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation. J Gastroenterol Hepatol 2012; 27: 1353-61.

  32. Zhu R, Ou Z, Ruan X, Gong J. Role of liver X receptors in cholesterol efflux and inflammatory signaling. Mol Med Rep 2012; 5: 895-900.

  33. Liu Y, De K Qiu, Ma X. Liver X receptors bridge hepatic lipid metabolism and inflammation. J Dig Dis 2012; 13: 69-74.

  34. Myhre AE, Agren J, Dahle MK, Tamburstuen MV, Lyngstadaas SP, Collins AJ, Foster SJ, et al. Liver X receptor is a key regulator of cytokine release in human monocytes. Shock 2008; 29: 468-74.

  35. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-9.

  36. Liu Y, Han X, Bian Z, Peng Y, You Z, Wang Q, Chen X, et al. Activation of liver X receptors attenuates endotoxininduced liver injury in mice with nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57: 390-8.

  37. Wang YY, Dahle MK, Agren J, Myhre AE, Reinholt FP, Foster SJ, Collins JL, et al. Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock 2006; 25: 141-6.

  38. Xu L, Kim JK, Bai Q, Zhang X, Kakiyama G, Min HK, Sanyal AJ, et al. 5-cholesten-3beta,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol 2013; 83: 648-58.

  39. Ikegami T, Hyogo H, Honda A, Miyazaki T, Tokushige K, Hashimoto E, Inui K, et al. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J Gastroenterol 2012; 47: 1257-66.

  40. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366: 377-91.

  41. Beier K, Volkl A, Fahimi HD. Suppression of peroxisomal lipid beta-oxidation enzymes of TNF-alpha. FEBS Lett 1992; 310: 273-6.

  42. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Experimental biology and medicine 2007; 232: 614-21.

  43. Pandey AK, Munjal N, Datta M. Gene expression profiling and network analysis reveals lipid and steroid metabolism to be the most favored by TNFalpha in HepG2 cells. PLoS One 2010; 5: e9063.

  44. Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, Gaudin F, Naveau S, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012; 57: 141-9.

  45. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-9.

  46. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anatomical record 2008; 291: 684-92.

  47. Kim JK. Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab 2006. 4: 417-9.

  48. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-98.

  49. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology 2008; 48: 670-8.

  50. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013; 73: 1-14.

  51. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006; 291: E275-E281.

  52. Nolan CJ, Larter CZ. Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it. J Gastroenterol Hepatol 2009; 24: 703-6.

  53. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23: 1635-48.

  54. Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-68.

  55. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-1403, 1403. e1-5.

  56. Bieghs V, Verheyen F, van Gorp PJ, Hendrikx T, Wouters K, Lutjohann D, Gijbels MJ, et al. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS One 2012; 7: e34378.

  57. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, et al. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res 2003; 44: 2270-7.

  58. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.

  59. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-305.

  60. Wu CX, Sun H, Liu Q, Guo H, Gong JP. LPS induces HMGB1 relocation and release by activating the NF-kappa B-CBP signal transduction pathway in the murine macrophagelike cell line RAW264.7. J Surg Res 2012; 175: 88-100.

  61. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.

  62. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.

  63. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005; 42: 585-91.

  64. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-78.

  65. Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, Romano AD, Sastre J, et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008; 57: 957-65.

  66. Fulop P, Derdak Z, Sheets A, Sabo E, Berthiaume EP, Resnick MB, Wands JR, et al. Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology 2006; 44: 592-601.

  67. Dara L, Ji C, Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology 2011; 53: 1752-63.

  68. Leclercq IA, Van Rooyen DM, Farrell GC. Hepatic endoplasmic reticulum stress in obesity: deeper insights into processes, but are they relevant to nonalcoholic steatohepatitis. Hepatology 2011; 54: 2260-5.

  69. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. J Gastroenterol Hepatol 2011; 26: 173-9.

  70. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12.

  71. Tang T, Sui Y, Lian M, Li Z, Hua J. Pro-inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death. PLoS One 2013; 8: e81949.

  72. Joka D, Wahl K; Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55: 455-64.

  73. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012; 56: 1291-9.

  74. Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun. Hepatology 2011; 54: 1496-9.

  75. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10: 277-86.




2020     |     www.medigraphic.com